AKT1 and neoplasm: As the PI3K/AKT pathway is one of the most commonly dysregulated pathways in cancer [53], future work will investigate whether ASAP1 overexpression can activate AKT signaling in cancer cells, and whether this impacts on the treatment of tumor patients with amplified or overexpressed ASAP1.